TABLE 3.
Associations between statin use and prostate cancer risk in a population-based case-control study, King County, Washington, 2002–2005
| Cases (n = 1,001) |
Controls (n = 942) |
OR*† | 95% CI* | |||
| No. | % | No. | % | |||
| Statin use | ||||||
| None | 712 | 71.1 | 677 | 71.9 | 1.00 | |
| Ever use | 289 | 28.9 | 265 | 28.1 | 0.98 | 0.80, 1.21 |
| Current use | 272 | 27.2 | 244 | 25.9 | 1.00 | 0.81, 1.24 |
| Duration of use (years) | ||||||
| <5.0 | 154 | 15.4 | 146 | 15.5 | 0.96 | 0.74, 1.23 |
| 5.0–9.9 | 90 | 9.0 | 81 | 8.6 | 0.97 | 0.70, 1.34 |
| ≥10 | 45 | 4.5 | 38 | 4.0 | 1.11 | 0.70, 1.75 |
| Continuous | 1.01 | 0.98, 1.03 | ||||
| Age at first use (years) | ||||||
| <59‡ | 166 | 16.6 | 138 | 14.6 | 1.11 | 0.86, 1.43 |
| ≥59 | 123 | 12.3 | 127 | 13.5 | 0.81 | 0.60, 1.07 |
| Time since first use (years) | ||||||
| <5 | 145 | 14.5 | 133 | 14.1 | 0.96 | 0.74, 1.24 |
| ≥5 | 144 | 14.4 | 132 | 14.0 | 0.97 | 0.75, 1.27 |
| Type of statin used§ | ||||||
| Hydrophilic | 42 | 4.2 | 42 | 4.5 | 0.91 | 0.58, 1.44 |
| Lipophilic | 274 | 27.4 | 246 | 26.1 | 1.02 | 0.83, 1.27 |
*
OR, odds ratio; CI, confidence interval.
†
Adjusted for age, race, and prostate cancer screening within the 5-year period before the reference date.
‡
Age 59 years was the median age at first use of a statin medication among controls.
§
Hydrophilic statins: pravastatin, rosuvastatin; lipophilic statins: lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin. Some cases (n = 27) and controls (n = 24) reported use of both types, so the analysis was also adjusted for the other type used.